| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
ChX710 targets the cytosolic DNA sensing pathway, specifically priming the type I interferon response to cytosolic DNA. The compound induces the ISRE promoter sequence and activates specific cellular interferon-stimulated genes (ISGs). ChX710's activity is dependent on the adaptor MAVS and IRF1, but not on IRF3, distinguishing it from direct STING agonists. The compound facilitates the phosphorylation of interferon regulatory factor 3 (IRF3), a critical transcription factor for type I interferon production. ChX710 activates the type I interferon response to cytosolic DNA by priming specific interferon-stimulated genes.
|
|---|---|
| ln Vitro |
ChX710 administration was reported to strongly synergistically affect IFN-β expression at the transcriptional and protein levels, eliciting cellular responses to STING DNA transfection [1].
ChX710 efficiently primes cellular response to transfected plasmid DNA as assessed by potent synergistic effects on IFN-β secretion and ISG expression levels. The compound induces the ISRE promoter sequence and specific cellular ISGs. ChX710 triggers the phosphorylation of IRF3. Although it is unable to trigger type I IFN secretion by itself, ChX710 treatment is found to efficiently prime the cellular response to DNA transfection via STING, as assessed by strong synergistic effects on IFN-β expression at both transcriptional and protein levels. |
| ln Vivo |
In vivo activity data for ChX710 are limited as the compound is primarily a research tool for studying the type I interferon response. As a primer of the cytosolic DNA sensing pathway, ChX710 would be expected to enhance interferon responses in vivo when combined with DNA-based stimuli or in the context of DNA-sensing pathway activation. The compound may be used in mouse models to study the role of type I interferon priming in immune responses to DNA viruses, tumors, or autoimmune conditions.
|
| Enzyme Assay |
The activity of ChX710 is assessed in cell-based assays measuring type I interferon responses. Cells (e.g., THP-1 macrophages or other relevant cell lines) are treated with ChX710 alone or in combination with transfected plasmid DNA. IFN-β secretion is measured by ELISA at both transcriptional (qPCR) and protein levels. ISG expression is assessed by qPCR for specific genes. ISRE promoter activity is measured using luciferase reporter assays. IRF3 phosphorylation is assessed by Western blot. Synergy between ChX710 and DNA transfection is calculated using standard synergy models.
|
| Cell Assay |
Cell-based assays for ChX710 are performed using appropriate cell lines such as THP-1 cells, macrophages, or other cells with functional cytosolic DNA sensing pathways. Cells are treated with ChX710 at varying concentrations (typically 0.1-10 μM) for 4-24 hours, with or without transfection of plasmid DNA using standard transfection reagents. IFN-β mRNA levels are measured by qRT-PCR, and secreted IFN-β protein is measured by ELISA. ISG expression (e.g., ISG15, ISG54, CXCL10) is assessed by qPCR. IRF3 phosphorylation is detected by Western blot using phospho-specific antibodies. Luciferase reporter assays using ISRE-luciferase constructs are used to quantify ISRE promoter activation.
|
| Animal Protocol |
In vivo studies for ChX710 would typically involve administration to mice (oral or intraperitoneal) followed by challenge with DNA-based immunostimulatory agents or infection with DNA viruses. Blood and tissue samples would be collected for measurement of IFN-β and ISG expression. The compound's ability to prime the type I interferon response would be assessed by comparing IFN and ISG levels in treated versus control animals. However, detailed published in vivo protocols for ChX710 are limited as the compound is a research tool.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for ChX710 are not extensively published. The compound has molecular formula C18H21N5O and belongs to the 1H-benzimidazole-4-carboxamide class. As a small molecule, it is expected to have reasonable membrane permeability and oral bioavailability. Standard pharmacokinetic studies would be required for any therapeutic development. The compound is available as a research reagent for in vitro studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for ChX710 are limited as it is a research compound. As a modulator of the type I interferon pathway, potential toxicities would be related to excessive interferon production, which could lead to inflammatory responses or autoimmune-like effects. Standard preclinical safety assessments would be required prior to any therapeutic use. The compound should be handled with appropriate laboratory safety precautions.
|
| References | |
| Additional Infomation |
ChX710 is a research-use only compound for studying the type I interferon response to cytosolic DNA. It is a small molecule ISRE inducer that primes the type I interferon response in a MAVS- and IRF1-dependent manner. The compound is useful for studying the mechanisms of cytosolic DNA sensing and the regulation of type I interferon responses, with potential applications in immunology, virology, and cancer research.
|
| Molecular Formula |
C18H21N5O
|
|---|---|
| Molecular Weight |
323.392243146896
|
| Exact Mass |
323.174
|
| CAS # |
2438721-44-7
|
| PubChem CID |
135397145
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=CC2=C1N=C(C1C=CN=CC=1)N2)NC(C)CN(C)C
|
| InChi Key |
HCAALGAOSBFHFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H21N5O/c1-12(11-23(2)3)20-18(24)14-5-4-6-15-16(14)22-17(21-15)13-7-9-19-10-8-13/h4-10,12H,11H2,1-3H3,(H,20,24)(H,21,22)
|
| Chemical Name |
N-[1-(dimethylamino)propan-2-yl]-2-pyridin-4-yl-1H-benzimidazole-4-carboxamide
|
| Synonyms |
ChX-710ChX 710ChX710
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~154.61 mM)
DMSO : ~20 mg/mL (~61.84 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (2.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0922 mL | 15.4612 mL | 30.9224 mL | |
| 5 mM | 0.6184 mL | 3.0922 mL | 6.1845 mL | |
| 10 mM | 0.3092 mL | 1.5461 mL | 3.0922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
